Does crizotinib work better in reducing the chest pain of ALKpositive non-small cell lung cancer patients compared with chemotherapy? by Sun, Qian
Philadelphia College of Osteopathic Medicine 
DigitalCommons@PCOM 
PCOM Physician Assistant Studies Student 
Scholarship Student Dissertations, Theses and Papers 
2020 
Does crizotinib work better in reducing the chest pain of 
ALKpositive non-small cell lung cancer patients compared with 
chemotherapy? 
Qian Sun 
Philadelphia College of Osteopathic Medicine 
Follow this and additional works at: https://digitalcommons.pcom.edu/pa_systematic_reviews 
 Part of the Medicine and Health Sciences Commons 
Recommended Citation 
Sun, Qian, "Does crizotinib work better in reducing the chest pain of ALKpositive non-small cell lung 
cancer patients compared with chemotherapy?" (2020). PCOM Physician Assistant Studies Student 
Scholarship. 506. 
https://digitalcommons.pcom.edu/pa_systematic_reviews/506 
This Selective Evidence-Based Medicine Review is brought to you for free and open access by the Student 
Dissertations, Theses and Papers at DigitalCommons@PCOM. It has been accepted for inclusion in PCOM 
Physician Assistant Studies Student Scholarship by an authorized administrator of DigitalCommons@PCOM. For 
more information, please contact library@pcom.edu. 
Does crizotinib work better in reducing the chest pain of ALK-









Qian Sun, PA-S  
A SELECTIVE EVIDENCE BASED MEDICINE REVIEW 
In Partial Fulfillment of the Requirements For  
The Degree of Master of Science 
In 
Health Sciences – Physician Assistant 
 
 
Department of Physician Assistant Studies 























Objective: The objective of this EBM review is to determine whether or not crizotinib works better 
in reducing the chest pain of ALK-positive non-small cell lung cancer (NSCLC) patients compared 
with chemotherapy. 
 
Study Design: This paper evaluates three randomized controlled trials (RCTs), which were all 
published in peer-reviewed journals in English after 2013. 
 
Data Sources: Three RCTs comparing the efficacy of crizotinib in reducing the chest pain in ALK-
positive non-small cell lung cancer patients with chemotherapy including pemetrexed and 
docetaxel.  Articles were selected via PubMed based on the outcomes of the studies mattered to 
patients (POEM). 
 
Outcomes Measured: The European Organisation for Research and Treatment of Cancer Quality 
of Life Questionnaire 13-item lung cancer module (EORTC QLQ-LC13) was completed by 
patients, the scores were used to measure lung cancer specific symptoms including chest pain. 
 
Results: All the three RCTs articles (Shaw 2013, Solomon, 2014, Blackhall 2014) showed that 
crizotinib is more effective in decreasing the chest pain in ALK-positive NSCLC patients than 
chemotherapy (P<0.001 [pemetrexed or docetaxel], P<0.001 [pemetrexed], P<0.05 [pemetrexed] 
and P<0.001 [docetaxel]).  All these studies suggest that crizotinib is superior to chemotherapy 
(pemetrexed or docetaxel) in reducing chest pain for ALK-positive NSCLC patients. 
 
Conclusions: The data analysis of these studies indicates crizotinib works better in reducing the 
chest pain in ALK-positive NSCLC patients compared with chemotherapy including pemetrexed 
and docetaxel.  The studies are limited to ALK-positive NSCLC patients. The treatments in the 
studies are not double-blinded, chest pain could be caused by other factors such as anxiety, which 
were not evaluated in this study. 
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Introduction 
The cell is the basic unit in the human body, it normally goes through growth, proliferation, 
differentiation, and death.  When a series of genetic changes occur in the cells, they gain the ability 
to escape from the cell division and cell death control.  Uncontrolled cell growth could form a 
tumor (solid tumor) or generate many immature cells (liquid tumor).  Cancer occurs when the 
tumor becomes invasive and spreads to nearby tissues or even distant organs.  Cancer cells affect 
the normal organs function, eventually cause organ failure and death. 
Cancer can occur almost anywhere in the body.  Lung cancer is an abnormal overgrowth 
of lung tissue cells, may spread to lymph nodes and other organs such as the liver, brain, or bone.  
Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are two major types of 
lung cancer.1  More than 80% of lung cancers are NSCLC which includes adenocarcinoma, 
squamous cell carcinoma, and large cell carcinoma.1  Adenocarcinoma is the most common form 
of lung cancer in the United States for both men and women which arises from the glandular tissue 
that lines inside of the lung.1  Anaplastic lymphoma kinase (ALK) gene encodes ALK receptor 
tyrosine kinase which actives a signaling pathway that plays an important role in regulating cell 
growth.2,3  ALK gene mutation involved NSCLC is called ALK-positive NSCLC.  The majority of 
ALK-positive NSCLC patients are young, female, and normally diagnosed before 50.4  The most 
common risk factor for NSCLC is smoking, however, ALK-positive NSCLC was found to have no 
strong association with smoking or environmental toxins.4 
Lung cancer is the 2nd most common cancer and the leading cause of cancer death in both 
men and women in the United States.5  The Centers for Disease Control and Prevention (CDC) 
statistical study shows 218,229 new cases of lung cancer in the United States in 2016.6   NSCLC 
is accounting for 85% of all lung cancer, and about 1 of 25 NSCLC patients is ALK-positive 
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NSCLC.7,8  The national expenditure of NSCLS was approximately $13.6 billion in the United 
States in 2016.9  The American Cancer Society estimates about 228,150 new lung cancer cases 
and about 142,670 deaths from lung cancer in 2019 in the United States.5 
Early stage lung cancer is normally asymptomatic; the symptoms in advanced lung cancer 
include cough, coughing up blood, shortness of breath, unintentional weight loss, chest pain, 
hoarseness, bone pain, and headache.10  The chest pain is one of the most common symptoms. 
Surgery is the standard treatment for localized NSCLC; radiation therapy is usually used 
before surgery to shrink lung tumor or after surgery to kill any possible missed tumor.11  
Combination platinum-based chemotherapy such as carboplatin and paclitaxel or carboplatin and 
pemetrexed are commonly used for locally advanced NSCLC, metastatic NSCLC, or after 
surgery.12  Chemotherapy generally targets fast-growing and dividing cells which is not specific 
and works throughout the body.  In the past decade, targeted therapies are used to treat patients 
based on the characteristics of the tumor, molecular tests are used to determine the gene mutations 
or rearrangements and guide the treatment.13  Another cancer treatment approach, called 
immunotherapy or biologic therapy, is used to boost the body’s immune system to fight cancer 
cells.14 
Crizotinib is the first targeted therapy drug designed for ALK-positive NSCLC by targeting 
both MET and ALK receptor tyrosine kinases.15  Studies have shown crizotinib significantly 
increases progression-free survival time in ALK-positive NSCLC patients compared with 
chemotherapy (pemetrexed and docetaxel).16,17,18  As the progression-free survival time in ALK-
positive NSCLC patients prolonged in crizotinib treatment group, it is reasonable to predict that 
crizotinib improves key lung-cancer symptoms (cough, dyspnea, chest pain, and fatigue) and 
overall quality of life as well. 
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Objective 
The objective of this systematic review is to determine whether or not crizotinib works 




This paper evaluates three randomized controlled trials comparing the efficacy of crizotinib 
in reducing the chest pain in ALK-positive non-small cell lung cancer patients with chemotherapy.  
The patients of the review are the age of 18 years or older with locally advanced or 
metastatic NSCLC that was positive for an ALK rearrangement.16,17,18  The Response Evaluation 
Criteria in Solid Tumors (RECIST) version 1.1 was used to evaluate the patients, characteristics 
of the patients include age, sex, race, smoking status, histology of disease, Eastern Cooperative 
Oncology Group performance status, extent of disease, and brain metastases.19  Two comparison 
groups of patients are evaluated, one never had chemotherapy and another group had one prior 
platinum-based chemotherapy regimen.  In this review one of the most common lung cancer 
symptoms — the chest pain — is primarily evaluated by comparing crizotinib treatment or 
chemotherapy. 
The three randomized controlled trials (RCTs) for this review were searched via PubMed, 
the articles were selected based on the outcomes of the studies mattered to patients (POEM).  All 
the articles were published in peer-reviewed journals and written in English.  Other criteria for the 
studies include RCT studies published after 2013 and the exclusion of non-ALK-positive NSCLC 
or SCLC patients.  Keywords used in searching the articles are: crizotinib, ALK-positive NSCLC, 
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chest pain, and chemotherapy.  Summary of statistics was reported as mean, SD, and p-value.  
Demographics and characteristics of this study are as follow (Table 1): 
Table 1. Demographics and Characteristics 
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Outcomes Measured 
In this review, the primary focus of the outcome was the reduction of chest pain in ALK-
positive NSCLC patients with crizotinib treatment or chemotherapy.  The European Organisation 
for Research and Treatment of Cancer Quality of Life Questionnaire 13-item lung cancer module 
(EORTC QLQ-LC13) was completed by patients, the scores were used to measure lung cancer 
specific symptoms including chest pain.16,17,18  Patient-reported outcomes of the chest pain had a 
baseline assessment and at least one post-baseline assessment.16,17,18  The chest pain could also be 
caused by other factors such as anxiety or depression, which were not evaluated in this study.  The 
progression-free survival time was evaluated and will not be discussed in this study. 
 
Results 
 An open-label, phase 3 trial study conducted by Shaw et al. with 347 ALK-positive NSCLC 
patients who had received one prior platinum-based regimen were randomly assigned to receive 
crizotinib (250 mg, twice daily) or intravenous chemotherapy – pemetrexed (500 mg per square 
meter of body surface area) or docetaxel (75 mg per square meter).16  Among the 347 patients, 173 
of them received crizotinib and 174 received chemotherapy.16  Patients in the chemotherapy group 
were allowed to cross over to crizotinib as part of a separate study.16 
 Questionnaires including EORTC QLQ LC-13 to measure patient-reported outcomes 
(PRO) were given at day 1 as the baseline and at every 3-week subsequent cycle, the primary end 
point was progression-free survival (PFS).16  The chest pain is one of the items in EORTC QLQ 
LC-13.  PROs were evaluated in patients with a baseline assessment and at least one post treatment 
assessment using repeated-measures mixed-effects modeling to compare crizotinib group and 
chemotherapy group by the overall change from baseline scores on EORTC QLQ LC-13.16  The 
Sun, Crizotinib in ALK-positive NSCLC   6 
 
raw scores were standardized into a range from 0-100 with 100 presenting the highest symptom 
severity, every 10 points change from baseline consider as clinically meaningful.20  The mean 
reduction in symptom score was measured, the chest pain has a significantly greater reduction 
from the baseline in crizotinib group than in chemotherapy group with patients who had one prior 
platinum-based regimen (P<0.001; Table 2).16 
 








 Another similar study was conducted by Solomon et al.; 343 ALK-positive NSCLC patients 
who had no previous systemic treatment were randomized to receive crizotinib (250 mg, twice 
daily) or intravenous chemotherapy (pemetrexed, 500 mg per square meter of body surface area, 
plus either cisplatin, 75 mg per square meter, or carboplatin, target area under the curve of 5-6 mg 
per milliliter per minute).17  Total 172 of the patients were in crizotinib group, and 171 of them 
were in chemotherapy group.  Crossover to crizotinib treatment from chemotherapy group was 
allowed if disease progressed.17  Measurement and data analysis for the chest pain in two different 
groups were similar to the first study.  The overall change from baseline for the chest pain has a 
great reduction in the crizotinib group than in the chemotherapy group with patients had previous 
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The last study by Blackhallet al. included 344 ALK-positive NSCLC patients who had 
received one prior platinum-based regimen.18  Patients were randomly assigned to receive 
crizotinib (173 patients, 250 mg, twice daily) or intravenous chemotherapy (171 patients, 
pemetrexed: 500 mg per square meter or docetaxel: 75 mg per square meter) in a 1:1 ratio.18  No 
cross over in the two groups were permitted.18 
 The scores of questionnaires EORTC QLQ LC-13 were measured and standardized using 
the same methods as the last two studies.18  The scores were compared between the crizotinib 
group and each of the chemotherapy subgroups (pemetrexed and docetaxel) in: 1. mean change 
from baseline; 2. the proportion of patients with improved or worse outcomes.18  Docetaxel and 
pemetrexed were associated with a significant worsening of chest pain in comparing with 
crizotinib (P<0.001; Table 4).18  In Table 4, a score difference of less than zero indicated crizotinib 
favors reduced chest pain, while a score of greater than zero indicated chemotherapy resulted in 
less chest pain, and zero value means no difference between crizotinib and chemotherapy.  The 
chest pain was also found to improve in more patients on crizotinib group than on chemotherapy 
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Crizotinib vs. Pemetrexed Crizotinib vs. Docetaxel 
Estimated diff. of Chest Pain 
-12.54 (-16.71 to -8.37) 
(95% CI, P<0.001) 
-14.36(-21.18 to -7.53) 
(95% CI, P<0.001) 
 
Table 5. The proportion of patients with improvement and worsening in chest pain in the crizotinib 
group vs. chemotherapy group. 
 
Chest Pain Crizotinib Pemetrexed Docetaxel 
Improvement Rates 
(P<0.001) 
40% 28% 15% 
Worsening Rates 
(P<0.05) 
8% 21% 39% 
 
Discussion and Conclusion 
 For advanced NSCLC,  palliation of symptoms and improvement in health-related quality 
of life are more important when the disease is incurable.  Chest pain is one of the major symptoms 
of any kind of lung cancer.  Platinum-based double-agent chemotherapy was generally the standard 
treatment for NSCLC.21  Crizotinib is the first targeted therapy drug designed for ALK-positive 
NSCLC.15  Studies indicated in ALK-positive NSCLC patients crizotinib was significantly greater 
in reducing lung cancer symptoms including chest pain comparing with chemotherapy, which is 
independent of the type of chemotherapy (pemetrexed or docetaxel), the performance status of the 
patients, the race of patients, the presence or absence of brain metastases, and previous systematic 
treatment or not.16,17,18  Crizotinib treatment also resulted in longer PFS, greater improvement in 
global quality of life, but overall survival did not have significant change between crizotinib and 
chemotherapy.16,17 
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 The EORTC tools used in these studies were previously validated to be clinically 
significant when there is a 10-point or greater change, the chest pain improvement reported from 
these studies are highly clinically relevant.18  The significant improvement of chest pain, as well 
as general health status, were observed in crizotinib treatment, but not in either type of 
chemotherapy.16,17,18  It is debatable that the outcome report was based on patients’ reports but not 
physicians, also patients with the disease were possible more adapted to the symptoms.  All these 
studies are open-label trials which could potentially cause patients’ bias in their self-report 
outcomes based on the different treatment expectation.  Different compliance between the two 
treatment groups could also be another limitation. 
 In conclusion, crizotinib demonstrates consistent improvement compared with 
chemotherapy (docetaxel or pemetrexed) in chest pain and other key lung cancer symptoms, as 
well as on the global quality of life and general health status.  As an inhibitor of Met and ALK, 
crizotinib has the potential to treat different types of cancers which contain Met or ALK mutations 
such as colorectal cancer, liver cancer, or gastric carcinoma.  Further research can include the study 
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